Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Shares Outstanding (Weighted Average) (2016 - 2025)

Lipocine (LPCN) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $5.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) changed 0.44% year-over-year to $5.4 million, compared with a TTM value of $5.4 million through Sep 2025, changed 0.44%, and an annual FY2024 reading of $5.3 million, up 1.31% over the prior year.
  • Shares Outstanding (Weighted Average) was $5.4 million for Q3 2025 at Lipocine, roughly flat from $5.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $88.3 million in Q1 2022 and bottomed at $5.2 million in Q2 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $26.6 million, with a median of $5.3 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 98.03% in 2021, then tumbled 94.07% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $86.9 million in 2021, then plummeted by 93.98% to $5.2 million in 2022, then rose by 0.73% to $5.3 million in 2023, then increased by 1.31% to $5.3 million in 2024, then increased by 0.61% to $5.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for LPCN at $5.4 million in Q3 2025, $5.4 million in Q2 2025, and $5.3 million in Q1 2025.